榮昌生物(688331.SH):泰它西普治療重症肌無力Ⅲ期臨牀研究達到主要研究終點
格隆匯8月13日丨榮昌生物(688331.SH)公佈,自主研發的BLyS/APRIL雙靶點融合蛋白創新藥泰它西普(RC18,商品名:泰愛)用於治療全身型重症肌無力(gMG)的Ⅲ期臨牀研究,達到方案設計的臨牀試驗主要研究終點。泰它西普已經在中國完成治療重症肌無力的Ⅲ期臨牀研究,達到方案設計的臨牀試驗主要研究終點。臨牀研究結果顯示,泰它西普可持續有效改善全身型重症肌無力患者的臨牀症狀,顯示良好的療效和安全性。公司將擇機向國家藥品監督管理局藥品審評中心(CDE)遞交上市申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.